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ABSTRACT
Purpose The effects of chitosan hydrochloride on the oral absorp-
tion of acyclovir in humans were studied to confirm the absorption
enhancing effects reported for in vitro and rat studies, respectively.
Methods A controlled, open-label, randomized, 3-phase study
was conducted in 12 healthy human volunteers. Zovirax 200 mg
dispersible tablets co-administered with doses of 400 and
1000 mg chitosan HCl were compared with Zovirax only.
Results The expected increased absorption of acyclovir was not
observed. On the contrary, mean area under the plasma
concentration-time curve (AUC0-12 h) and maximal plasma con-
centration (Cmax) decreased following concomitant chitosan in-
take (1402 versus 1017 and 982.0 ng∙h/ml and 373 versus 208
and 235 ng/ml, respectively). In addition, Tmax increased signifi-
cantly in presence of 1000 mg of chitosan from 1 to 2 h.
Conclusions The results of this study in human volunteers did
not confirm an absorption enhancing effect of chitosan. Reference
values were comparable to literature data, whereas addition of
chitosan resulted in significant opposite effects on Cmax, Tmax and
AUC. Additional studies are needed to investigate the cause of the
discrepancy. The observed variability and complex potential inter-
actions may complicate the use of chitosan HCl in oral pharma-
ceutical formulations.
KEY WORDS bioavailability . biopharmaceutics classification
system . biowaiver . excipient interactions . pharmacokinetics
ABBREVIATIONS
(HP)LC (High pressure) liquid chromatography
AUC Area under the curve
AUC Area under the curve
BCS Biopharmaceutics classification system
CI Confidence interval
Cmax Maximum plasma concentration
CV Coefficient of variation
DD Degree of deacetylation
EMA European Medicines Agency







Tmax Time point at which the maximum concentration is
measured
INTRODUCTION
Permeation enhancement has been a research topic in
pharmaceutics for decades. Increasing the absorption of drugs
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with low permeability may for instance aid the reduction of
the variability in bioavailability as well as reduce the adminis-
tered dose of an active substance. Examples of absorption
modulators are acetylcystein, supposedly acting via reduction
of the mucous layer by disrupting disulfide bridges; surfac-
tants, polymers and chelating agents potentially interfering
with the tight junctions, and substances interfering with ab-
sorption or efflux transporters (1–3).
Chitosan and its derivatives have been described as poten-
tial permeability enhancers acting via a disruptive effect on the
tight junctions between the epithelial cells (4–9). Chitosan is a
heteropolysaccharide derived from natural source; character-
ized by variable molecular weights, degrees of deacetylation
(DD) and salt forms (10).
Acyclovir is a BCS class III substance that is predominantly
absorbed via the paracellullar route and has a low and variable
bioavailability of 10–30% (11,12). Some studies suggest the
existence of a saturable carrier system or a limited absorption
window.Most of the drug is renally excreted in untransformed
state (13,14). Chitosan was shown to increase the in vitro per-
meability of acyclovir across Caco-2 monolayers and the ab-
sorption of acyclovir in the rat (15–17). In the absence of
clinical studies in humans, the translation of these effects in
cell culture and animal models to humans currently remains
unclear. The aim of the study presented here was to test the
effects of chitosan hydrochloride on the oral absorption of
acyclovir in human volunteers.
MATERIALS AND METHODS
Materials
Zovirax 200 mg dispersible tablets (GlaxoSmithKline, Austrian
license number 1-18043) were used as reference product. Chito-
san hydrochloride (chitosan HCl) of pharmacopoeial quality was
obtained from Heppe Medical, Halle; degree of deacetylation
(DD) 93.05%, viscosity 1% inwater at 20°C 5.9mPas,molecular
weight (MW) 30–400 kDa. It was dispensed into quantities of
400 and 1000 mg and labeled by Löwen Apotheke in
Hochspeyer, Germany. The powders released by the Depart-
ment of Pharmaceutical Technology and Biopharmaceutics of
the Johannes GutenbergUniversity inMainz, Germany. Acyclo-
vir reference material was purchased from Fagron. All other
materials were purchased from Sigma Aldrich.
Study Design
A controlled, open-label, randomized, 3-phase study was con-
ducted at the Clinical Research Center of the University Hos-
pital inMainz, Germany. The clinical trial protocol (EudraCT-
Nr. 2010-023882-22) was approved by both the relevant Ethics
Committee (Landesärztekammer Rheinland-Pfalz) and the
German competent authorities (Bundesinstitut für Arzneimittel
undMedizinprodukte, BfArM) and the study was performed in
accordance with the Declaration of Helsinki. Adult, male and
female healthy volunteers were included after a health check
based on interview, blood pressure, blood parameters and
ECG. Taking into account the variation coefficients as present-
ed previously by Vergin et al. in a bioequivalence study with
200 mg acyclovir products and considering an estimated min-
imum effect size of 30% as potentially clinically relevant, a
number of 12 volunteers was selected for this exploratory study
(18). Participants did not take part in another clinical study in
parallel and did not take part in one within the preceding
90 days. Other exclusion criteria were: alcohol abuse or med-
ication dependency in anamnesis, known hypersensitivity to
study medication, active liver disease or unexplained increased
levels of serum transaminases, intake of prescription drugs in
the last 1–2 months, a recent (90 days) history of cytomegalovi-
rus or systemic herpes infection(s) or recurrent systemic infec-
tions of herpes viruses, pregnancy and lactation, renal dysfunc-
tion. The subjects received Zovirax on the first trial day and
were then randomly assigned to either the sequence 1000 mg
followed by 400 mg chitosan HCl or vice versa. This resulted in a
2-treatment (400 vs 1000 mg chitosan HCl), 2-sequence cross-
over design with pretreatment by Zovirax. This study design
allowed evaluation of the pharmacokinetics of acyclovir, with-
out potential interference of chitosan. A wash-out phase of
7 days was applied for each treatment.
Zovirax tablets were used as reference and the same tablets,
co-administered with a known quantity of chitosan HCl, were
used as test ‘formulations’. All products were dispersed in
100 mL water and administered with another 150 mL,
resulting in a total volume of 250 mL water. Start concentra-
tions of 1.6 g/L (0.16%) and 4.0 g/L (0.4%) chitosan HCl were
thus obtained, in line with those described in literature (0.1%–
0.5%) (15,16). The maximum chitosan dose was limited to 1 g
in view of the practical feasibility of oral intake of the quantity as
a single dose and the related limited relevance of higher quan-
tities as a potential excipient in an actual solid oral dosage form.
Subjects entered the studies fasting for at least 9.5 h. The
first meal was offered 4 h post-dose. The medication was ad-
ministered with a total of 250 mL water; subjects had access to
more water from 1 h post-dose on and consumed at least 1.4 L
mineral water during the 12 h trial. Blood samples were col-
lected prior to administration of the product(s) and at 0.25,
0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 h after dosing. Blood
samples were centrifuged for separation of plasma and stored
at or below −20°C prior to analysis.
HPLC Assay
Plasma samples of 500 μl were prepared for analysis by solid
phase extraction, using Oasis HLB 1 cc cartridges (30 mg)
supplied by Waters. The column was washed with 500 ml
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water and then eluted with 500 μl acetonitrile. The extract
was centrifuged at 14000 rpm for 10 min at −5°C and the
concentration of acyclovir was determined by LC-MS/MS
using a sample injection volume of 10 μl. The bioanalytical
method was modified from previously reported methods
(16,19,20). Validation data are included as supplementary
material. The HPLC consisted of a Prontosil C18; 100*2,
00 mm; 5 μm column, using an Agilent 1100 LC binary
pump. A gradient elution was used with mobile phase A and
B where A consisted of 15mM ammonium acetate+0.1375%
formic acid at pH 3.5 and B was acetonitrile+0.1375%
formic acid. Details of the gradient:
Step Total Time(min) Flow Rate(μl/min) A (%) B (%)
0 0.00 300 97.0 3.0
1 0.50 300 97.0 3.0
2 0.60 300 5.0 95.0
3 1.20 300 5.0 95.0
4 2.00 300 97.0 3.0
5 5.50 300 97.0 3.0
Detection took place by a triple quadrupole LC-MS/MS
mass spectrometer, API 3000 manufactured by AB Sciex In-
struments, using multiple reactions monitoring with transi-
tions Q1/Q3: 255,992→151,873. Source temperature was
500°C, overall run time was 5.5 min. The method was linear
in a range of 10 to 800 ng/ml, with a detection limit of
1 ng/ml. QC samples were analyzed with the plasma samples
to monitor method accuracy and precision.
Pharmacokinetic and Statistical Analysis
The data were analyzed using Microsoft Excel 2010 and IBM
SPSS Statistics version 19. Maximum plasma concentration,
Cmax, and the time point at which this was measured, Tmax,
were manually selected from the data. The areas under the
curve, AUC(0-t) and AUC(0-∞), were estimated using the linear
trapezoidal method as available in PKSolver2.0 with auto-
matic calculation of the terminal elimination slope using the
regression with the largest adjusted R2 based on at least three
of the last time points (21).
The complete dataset was analyzed for sequence or period
effects on Cmax and AUC using a general linear model with
period, treatment, sequence and subject within sequence as
fixed effects. The difference between related parameters was
considered statistically significant if p≤0.05.
Parametric 90% confidence intervals were calculated
based on the univariate ANOVA of the mean ratio of test
versus reference using log-transformed Cmax and AUC data.
An increase of the bioavailability of more than 30% was
predefined as clinically significant. In addition, the products
were evaluated based on the European Guideline on
bioequivalence. Test and reference products were considered
bioequivalent if the ln-transformed ratios of Cmax and AUC
and their confidence intervals were within the equivalence
range of 80–125% (22).
Tmax was analysed using the nonparametric Wilcoxon
signed rank test, where p≤0.05 was considered statistically
significant.
Tolerability
Tolerability was assessed by monitoring electrocardiogram
and blood parameters before and after the study and by sub-
ject interviews during the study.
RESULTS
Tolerability
The formulations were well tolerated. No adverse events were
reported.
Study Design and Data Evaluation
Table I shows the p-values of the potential treatment, period,
sequence and subject within sequence effects obtained for the
parameters AUC(0–12), AUC(0-∞) and Cmax, which were all
above 0.05. These data confirmed absence of period or se-
quence effects and justified pooling of the data of each of the
two doses of chitosan obtained at the two different time points.
The pooled data were compared to the data obtained with
reference product Zovirax.
Figures 1, 2, and 3 show the mean plasma curves obtained
and an overview of individual data. The individual plasma
profiles are accessible as supplementary material. The individ-
ual AUC data were considered sufficiently reliable as AUC(0–
12) was >80% AUC(0-∞) in all cases, except for one in a test
situation with 400 mg chitosan HCl where AUC(0–12) was
67% of AUC(0-∞). All data were used in the analysis..
Table I P- Values for Effects on AUC(0-12), AUC(0-∞) and Cmax
Source p-values (α=0.1)
AUC(0-12) AUC(0-∞) Cmax
Treatment 0.883 0.713 0.913
Period 0.900 0.975 0.544
Sequence 0.285 0.208 0.218
Subject within sequence 0.686 0.487 0.594
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Comparative Evaluation of Pharmacokinetic Data
Table II shows the pharmacokinetic data for each of the treat-
ments; including comparative data of previously reported
pharmacokinetic data of 200 mg doses of acyclovir. Cmax,
Tmax and AUC values of the reference product were of the
same magnitude as the data reported previously, both with
regard to the mean values as well as to standard deviations
(13,18). The mean values obtained for the Cmax and AUC in
presence of chitosan are lower than reference values reported
in literature, whereas the standard deviations for Cmax and
Tmax in presence of chitosan are higher. The elimination
half-lives are also similar to those reported by others.
Tables III and IV list the point estimate and the 90% con-
fidence interval for AUC andCmax for each of the two doses of
test product versus the reference product. Comparison of ref-
erence acyclovir with the two situations of concomitant chito-
san intake show that both the arithmetic mean of the original
data and the geometric mean of the ratios (GMR) of the AUC
and Cmax decreased in presence of chitosan. The individual
data show how in 9 out of 12 cases the Cmax and AUC values
of reference Zovirax are indeed higher than those of the com-
binations with chitosan.
The confidence intervals of the geometric mean ratios for
AUC(0–12) and AUC(0-∞) concerning 400 mg chitosan HCl,
included 1.00 and could thus not confirm a significant effect.
However, those for the 1000 mg dose of chitosan did not
include 1.00, pointing to a significant negative effect. The
lower boundary of the 90% confidence intervals for AUC(0–
12) and AUC(0-∞), 0.50 resp. 0.51, show how this decrease
could be up to about 2-fold compared to the reference value.
For Cmax, neither 90% confidence interval includes 1.00,
thereby demonstrating a significant decrease in Cmax of acy-
clovir in presence of both doses of chitosan. This effect is at
least 10% for the 400 mg dose and 12% for the 1000mg dose.
The confidence intervals for the 400 and 1000 mg doses al-
most completely overlap: the median effect is a decrease by
41–42% to values of 58–59% of the reference value (seeGMR
values). The decrease could be at maximum 61–62%, i.e. to
values as low as 38–39% of the reference Cmax, considering
the lower boundaries of the confidence intervals.
The Tmax obtained with 400 mg chitosan HCl is not sig-
nificantly different from the Tmax of the reference Zovirax.
However, Tmax increased significantly in presence of
1000 mg of chitosan from 1 to 2 h (p=0.029).
DISCUSSION
The results obtained with the acyclovir reference product
were in line with those published by others, both regarding
the magnitude of the mean values as well as the standard
deviations (see Table II).
The effects of chitosan on the bioavailability of acyclovir
from Zovirax were evaluated in the context of a pretreatment
with Zovirax, as administered to all volunteers on the first trial
day. In view of the half-life of acyclovir of about 3 h, a carry-
over effect of pretreatment with Zovirax is not expected to
play a role and the order of administration of the test and
reference products is not expected to affect the results (23).
Locally administered chitosan increased acyclovir’s perme-
ability across Caco-2 membranes and facilitated the absorp-
tion of acyclovir in rats (15–17). The clinical trial protocol was
based on an expected increase of Cmax and AUC and defined
that an increase by 30% would be considered as relevant.
However, chitosan HCl did not act as absorption enhancer
of acyclovir in the human study presented here. None of the
confidence intervals includes a value of 1.3 or more, so an
increase by 30% is highly unlikely.
Masuda et al. postulated a cut-off value of 10 kDa as min-
imal chain length of the chitosan polysaccharide to facilitate
acyclovir’s absorption. Opanasopit et al. showed an increasing
negative effect on the transepithelial electric resistance of
Caco-2 monolayers with increasing MW in the range of 20–
460 kDa (24). The applied chitosan had aMWof 30–400 kDa
which is well within these ranges. Masuda et al. also found a
dose dependent effect and the authors explained its transience
by dilution of the concentration at the site of action and by
neutralization of the acidified perfusate by the intestinal fluids.
Fig. 1 Mean acyclovir plasma profiles. For clarity of the figure, only one-way
error bars representing the standard deviation are shown. Positive bars are
shown for the Zovirax reference and for Zovirax with the 400 mg chitosan
dose (dashed line). Negative bars are shown for Zovirax with the 1000 mg
chitosan dose. The actual standard deviations were equal in both positive and
negative direction.
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An enhancing effect due to changes in viscosity or cationic
charges only was not found likely. Here, chitosan HCl and
acyclovir were administered orally and their concentrations
were diluted by the luminal fluids while progressing through
Fig. 2 Individual data for AUC(0-12).
Fig. 3 Individual data for Cmax.
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the gastrointestinal tract, probably resulting in insufficiently
high concentrations at acyclovir’s absorption site. Moreover,
the actually dissolved and protonated fraction of chitosan may
have been too low at gastrointestinal pH, thereby limiting a
charge-based interaction with the epithelial membrane (25).
Chitosan is metabolized in the colon, a property that has
been used to produce colon targeted formulations (26). Al-
though evidence suggests that chitosan metabolism is likely
to mainly take place in the colon, the concentration at acyclo-
vir’s absorption site may also have been decreased by enzy-
matic degradation in stomach (pepsin) and/or duodenum/
ileum (pancreatic enzymes) (27–32). In addition, the presence
of mucus may represent an unfavorable microenvironment
and have hampered the access of chitosan to the mucosa to
exert its permeability enhancing effect (33,34).
If the data were to be evaluated as a bioequivalence study,
a confidence interval contained within 0.8 to 1.25 would be
considered as bioequivalent and confirm absence of clinically
relevant difference. Considering the lower values of each of
the 90% confidence intervals, which are all well below 0.8, the
data do not confirm bioequivalence of the combination of
Zovirax with chitosan to Zovirax only. In fact, the data unex-
pectedly show a reduced bioavailability of acyclovir in pres-
ence of chitosan HCl. Cmax was significantly reduced by both
chitosan doses, and AUC and Tmax only by the 1000 mg
chitosan dose. Dose dependency could not be demonstrated
as point estimates for AUC and Cmax were close and the
confidence intervals for both doses of chitosan almost
completely overlap. Confirmatory studies may clarify the ac-
tual significance and magnitude of the observed negative ef-
fects on the means.
Acyclovir is known for its variable absorption. DeMiranda
and Blum described how a 200 mg acyclovir outperformed a
200 mg acyclovir solution in as many subjects as vice versa
thereby demonstrating how the variability in absorption is a
substance related characteristic and not product related (21).
Figures 2 and 3 also show variable individual effects in absence
and presence of chitosan: contrary to the results of the means,
three volunteers actually showed an increase of the bioavail-
ability for one of the chitosan doses. The standard deviations
calculated for AUC and Cmax remain comparable to litera-
ture data in presence of chitosan (see Table II). However, the
standard deviation for Tmax is higher than literature values for
the reference product. Several mechanisms may have influ-
enced the bioavailability of acyclovir. Considering the effects
on the variability of Tmax, the significant effects on Cmax and
AUC, and other hand, the similarity of the terminal half-lives
Table II Pharmacokinetic Data (Mean Values ± sd) of a 200 mg Dose of Acyclovir, Including Comparison with Literature




Reference (1) Reference (2) Reference (3)
Cmax
(mg/ml)
0.373±0.209 0.208±0.090 0.235±0.255 0.3±0.1 (c, s) 0.454±0.165 (t) 0.677±0.209 (t)
0.525±0.205 (r) 0.707±0.239 (r)
Tmax 1.2±0.4 1.5±0.9 1.8±0.9 1.5±0.6 (c) 1.6±0.7 (t) 1.5±0.5 (t)
(h) 1.2±0.3 (s) 1.6±0.7 (r) 1.5±0.4 (r)
AUC0-inf 1.528±0.627 1.132±0.418 1.074±0.509 1.5±0.5 (c) 2.375±0.739 (t) 3.422±1.309 (t)
(mg·h/ml) 1.6±0.5 (s) 2.632±0.927 (r) 3.518±1.211 (r)
(AUC0–24)
t1/2 3.4±1.1 3.5±1.0 3.2±0.6 2.9±0.8 (c) 3.15±0.60 (t) 4.49±2.37 (t)
(h) 2.9±0.7 (s) 3.04±0.58 (r) 3.93±2.65 (r)
1. de Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12 Suppl B:29–37.
2. Vergin H, Kikuta C, Mascher H, Metz R. Pharmacokinetics and bioavailability of different formulations of aciclovir. Arzneimittelforschung. 1995;45(4):508–15.
3. Rojanasthien N, Teekachunhatean S, Kumsorn B, Chaichana N, Hay YK. Bioequivalence study of generic acyclovir compared with the brand name acyclovir. J
Med Assoc Thail. 2002;85(10):1121–9.
t test, r reference tablet, c capsule, s solution
Table III Comparative Evaluation of 200 mg Zovirax p.o. Without









AUC(0–12) 0.72 0.51–1.13 46
AUC (0-∞) 0.73 0.54–1.00 42
Cmax 0.59 0.39–0.90 57
Table IV Comparative Evaluation of 200 mg Zovirax p.o. Without









AUC(0–12) 0.70 0.50–0.99 46
AUC (0-∞) 0.69 0.51–0.94 42
Cmax 0.58 0.38–0.88 57
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with reference values, chitosan’s effect seems to mainly take
place in the absorption phase.
Literature evidence does not point to interaction between
chitosan HCl and acyclovir leading to degradation of acyclo-
vir, either in a formulation or in the gut lumen. An effect of
chitosan HCl on the dissolution (rate) of acyclovir at the time
of administration is conceivable. The tablets were dispersed in
100 mL water or 100 mL chitosan solution and the glass was
rinsed with another 150 mL of water. In view of acyclovir’s
solubility of ≥2.3 mg/mL in pH range 1.2–7.4 at 37°C and
the expected final concentration 2 mg/mL in the first 100 mL
water at room temperature, not all acyclovir may have been
dissolved (35,36). However, after addition of 150ml water and
assuming the presence of additional volume of aqueous fluids
and a temperature of 37°C in the stomach, acyclovir was
expected to dissolve sufficiently well. Experiments [data not
shown] indeed confirmed the visual compatibility of 1 g chi-
tosanHCl with 200mg pure acyclovir after 1 min of stirring in
250 mL water at room temperature, resulting in a clear solu-
tion. In addition, any residues of undissolved acyclovir were
expected to be similar for reference and test situations.
Acyclovir’s solubility is at the borderline of BCS class III
and IV. Increasing its solubility in the lumen may improve its
bioavailability, as demonstrated by the effects of a self-
microemulsifying drug delivery system (37). Vice versa, its solu-
bility may become limiting if it is chemically or physiologically
reduced. Allam et al. showed how chitosan-acyclovir co-crys-
tals prolonged the release of acyclovir, however, the crystal
formation was not observed when acyclovir and chitosan were
dissolved in 250 mL water [data not shown] (38). Nadai et al.
showed how chitosan (25 mg/kg) prolonged Tmax of orally
administered suspensions of indomethacin and griseofulvin
in rats, and reduced Cmax and AUC. Association of the an-
ionic indomethacin to the tertiary amino groups of chitosan
did not play a role according to those authors (39). The mo-
lecular structures of chitosan (pKa ~6–6.5) and acyclovir
(pKa’s 2.3 and 9.3) do not seem to favor charge based com-
plex formation or adsorption either (40).
Effects on Tmax and Cmax may be related to the gastric
emptying time; whereas an effect on intestinal transit time
may be relevant for the absorption of the BCS class III com-
pound acyclovir. It was previously found unlikely that chitosan
caused alterations in the gastric emptying rate, as the delayed
Tmax was not observed for other compounds (39). However, in
the current case, the difference in stomach content after inges-
tion of the chitosan dispersion (increased osmotic value, lower
pH, perceived nutrient density) compared the reference disper-
sion may have influenced the gastric emptying rate which may
explain the variable effect on Cmax and Tmax.
Nadai et al. postulated an indirect effect as a cause
for the prolonged Tmax: binding of bile acids to chitosan
resulting in inhibition of the solubilisation of the drug
substances (39). Heinen et al. indeed described how
presence and reduction of bile salts affected the absorp-
tion of BCS class III drug trospium chloride (41). In
fact, the absorption of acyclovir increased in presence
of conjugated trihydroxy bile salts and bile salt-
acylcarnitine mixed micelles (42,43). The 1000 mg chi-
tosan HCl used in the clinical study presented here
corresponds to about 14 mg/kg for a human being of
70 kg and is thus of the same order of magnitude as the
dose used by Nadai et al. Although amphoteric acyclovir
is in neutral state at physiological pH and is not known
for having a significant food effect, chitosan may have
interacted with luminal bile components indirectly
resulting in a reduced bioavailability of acyclovir
(14,36).
Finally, chitosan may act at the site of absorption.
Chitosan’s mucoadhesive properties have been studied
in potentially absorption enhancing formulations of acy-
clovir (44–46). Although no literature evidence is known
to the authors, theoretically, chitosan may have physi-
cally or biochemically delayed or prevented access of
acyclovir to its paracellular permeation route by binding
to mucus at the absorption site and/or changing the
microclimate e.g. by formation of a protective viscous
layer. Derivatives of chitosan, quercetin and DM72
have been shown to inhibit the efflux of acyclovir via
P-gp, with the aim of improving its bioavailability
(47–49). An opposite effect, i.e. induction of (expression
of) P-gp by chitosan has not been described and seems
an unlikely effect of a single dose of chitosan.
An effect of chitosan on the metabolism of drugs has not
been described. As acyclovir is eliminated mainly in un-
changed form, such interaction is not considered likely either
(14).
As chitosan is currently not in use as an excipient in ap-
proved drug products, the clinical impact of the results seems
limited. However, the observed variability and complex po-
tential interactions may complicate the use of chitosan HCl in
oral pharmaceutical formulations. In addition, chitosan is ad-
vertised as food supplement in high doses, up to 6 g a day;
interactions with concomitant pharmacotherapy seem possi-
ble (50).
CONCLUSION
The results of this study in human volunteers did not confirm
the data obtained in in vitro experiments and in rats studies that
suggested that chitosan would improve the bioavailability of
acyclovir. Chitosan increased the variability of the absorption
of acyclovir and significantly reduced its absorption. Mecha-
nistic studies are needed to investigate the cause for the dis-
crepancy in these results. A luminal interaction of chitosan
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with acyclovir, bile salts or the epithelial membrane may be
responsible for the negative effects on acyclovir’s absorption.
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